Who is the CEO of MOA Life Plus?

According to the DART company overview, MOA Life Plus' representative director is 한상진 (name as registered in Korean). The company was founded on 1999-12-30.

Where is MOA Life Plus listed?

MOA Life Plus trades on the Korea Exchange KOSDAQ market under the ticker 142760. Its fiscal year ends in December.

Does MOA Life Plus pay a dividend?

MOA Life Plus did not pay a cash dividend for fiscal 2025, according to its annual report.

Does MOA Life Plus have any recent filing signals?

Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); 4 quarters of losses (operating loss in each of the last four quarters); Control change (change of largest shareholder, or a contract that would cause one (90 days)); Private placement (third-party allotment rights offering decided in the past 90 days). 2 more signals are shown on the page. These are factual flags, not investment advice.

Which companies are in the same industry as MOA Life Plus?

Under the Korean Standard Industrial Classification recorded on DART, MOA Life Plus is grouped with 77 other listed companies in research & development. The most covered in Korean news over the past 30 days are Alteogen, SK biopharmaceuticals and Onconic Therapeutics.

MOA Life Plus KRX:142760KOSDAQ

모아라이프플러스 · Korean news coverage and regulatory filings, organized.

한국어

Articles, 24h0

Articles, 7 days0

DART filings, 7 days7

Articles tracked9since Sep 11

In Q2 2026, MOA Life Plus reported revenue of ₩2.3bn, up 0.4% year on year, and an operating loss of ₩1.2bn. MOA Life Plus (모아라이프플러스) appeared in 0 Korean news articles and 7 DART filings over the past seven days. Coverage peaked on Oct 20 with 2 articles. It was most often mentioned alongside Bifido.

Filing signals Control change Private placement Dilution risk 4 quarters of losses Share pledge Delisting / halt risk Screener

MOA Life Plus quarterly results consolidated, KRW

Quarter	Revenue	YoY	Operating profit	Net income
Q2 2026	₩2.3bn	+0.4%	−₩1.2bn margin −52.8%	−₩7.9bn
Q1 2026	₩2.3bn	-24.7%	−₩1.4bn margin −58.2%	−₩1.1bn
Q4 2025 derived	₩4.6bn	+44.3%	−₩2.8bn margin −60.7%	−₩4.0bn
Q3 2025	₩1.2bn	-66.6%	−₩1.5bn margin −124.4%	−₩709m
Q2 2025	₩2.3bn	-41.1%	−₩1.2bn margin −50.9%	−₩7.0bn
Q1 2025	₩3.1bn	-37.3%	−₩1.1bn margin −34.7%	−₩1.3bn
Q4 2024 derived	₩3.2bn	-31.2%	−₩3.6bn margin −114.1%	−₩2.8bn
Q3 2024	₩3.5bn	-27.7%	−₩603m margin −17.0%	−₩1.7bn

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

MOA Life Plus top stories 2 weeks, by number of outlets

1
[이슈] 모아라이프플러스 'BEYUL' 할랄 인증 성공…무슬림 시장 '직행 티켓'
1 outlets · 1 articlesFirst report Oct 20 15:12 오늘경제
2
모아라이프플러스 40억원 유상증자 납입일 11월 10일로 변경
1 outlets · 1 articlesFirst report Oct 18 13:27 비건뉴스
3
고령화·헬스케어 수요 지속…모아라이프플러스·비피도 건기식주 방긋
1 outlets · 1 articlesFirst report Oct 20 09:49 핀포인트뉴스Bifido

Latest MOA Life Plus news Korean headlines

Oct 2015:12

[이슈] 모아라이프플러스 'BEYUL' 할랄 인증 성공…무슬림 시장 '직행 티켓'
오늘경제
Oct 2009:49

고령화·헬스케어 수요 지속…모아라이프플러스·비피도 건기식주 방긋
핀포인트뉴스Bifido
Oct 1813:27

모아라이프플러스 40억원 유상증자 납입일 11월 10일로 변경
비건뉴스
Sep 2909:58
모아라이프플러스, 40억 규모 유상증자 결정
이데일리
2 more on this story · 2 outlets
- 모아라이프플러스, 40억 규모 유상증자 결정이데일리 · Sep 29 09:55
- 모아라이프플러스, 40억 규모 유상증자 결정이데일리증권 · Sep 29 09:55
Sep 2907:36

모아라이프플러스, 40억원 유상증자…메드투자조합에 제3자배정
연합뉴스경제
Sep 1818:04

모아라이프플러스, 20억원 규모 유상증자 실시
매일경제
Sep 1615:00

모아라이프플러스, 20억원 유상증자…에이원성장투자조합에 제3자배정
연합뉴스경제

Articles per day 2 weeks

118

220

Company profile

CEO: 한상진
Industry: Research & development
Founded: 1999-12-30
Fiscal year-end: December
Head office: 경기도 용인시
Website: bioleaders.co.kr
Quotes & chart: Naver Securities (Korean)

From the DART company overview.

Major shareholders latest 5%+ report per holder

Korea 5% stake disclosures

모아데이타17.32%

Each holder's most recent 5% ownership report on DART; names as filed in Korean.

Same industry Research & development

All in industry

Company	Latest quarter op. profit	Articles 30d
Alteogen	₩34.2bn	225
SK biopharmaceuticals	₩97.1bn	118
Onconic Therapeutics	₩2.8bn	73
Qurient	−₩12.8bn	72
OliX Pharmaceuticals	−₩14.0bn	51
Rznomics	−₩6.9bn	47
SillaJen	−₩6.2bn	46
LigaChem Biosciences	−₩72.0bn	41

Compare MOA Life Plus side by side with these companies

MOA Life Plus DART filings

Oct 2917:24

Trading halt / delisting 기타시장안내 (주가 미달에 따른 상장폐지 우려 관련 안내)
Risk & warnings
Oct 2817:45

Change of largest shareholder [기재정정]최대주주변경을수반하는주식담보제공계약체결
Capital & M&A
Oct 2716:57

Other [기재정정]소액공모공시서류(지분증권)
Other
Oct 2716:53

Other [기재정정]의결권대리행사권유참고서류
Other
Oct 2716:50

Other [기재정정]주주총회소집공고
Other
Oct 2716:45

Rights offering [기재정정]주요사항보고서(유상증자결정)
Capital & M&A
Oct 2716:44

Other [기재정정]주주총회소집결의 (임시주주총회)
Other
Oct 2116:28

Other [기재정정]주요사항보고서(주권관련사채권양도결정)
Other
Oct 2016:39

Other [기재정정]주요사항보고서(주권관련사채권양도결정)
Other
Oct 1916:38

Other [기재정정]소액공모공시서류(지분증권)
Other
Oct 1916:31

Rights offering [기재정정]주요사항보고서(유상증자결정)
Capital & M&A
Oct 1615:55

Convertible bond [기재정정]주요사항보고서(전환사채권발행결정)
Capital & M&A

Mentioned alongside 2 weeks

1 BifidoKOSDAQ 1

MOA Life Plus FAQ

Who is the CEO of MOA Life Plus?: According to the DART company overview, MOA Life Plus' representative director is 한상진 (name as registered in Korean). The company was founded on 1999-12-30.
Where is MOA Life Plus listed?: MOA Life Plus trades on the Korea Exchange KOSDAQ market under the ticker 142760. Its fiscal year ends in December.
What were MOA Life Plus' latest quarterly results?: In Q2 2026, MOA Life Plus reported revenue of ₩2.3bn, up 0.4% year on year, and an operating loss of ₩1.2bn. Figures come from reports filed on DART.
Does MOA Life Plus pay a dividend?: MOA Life Plus did not pay a cash dividend for fiscal 2025, according to its annual report.
Does MOA Life Plus have any recent filing signals?: Signals detected automatically from DART filings and quarterly results: Dilution risk (rights offering or CB/BW/EB issue decided in the past 90 days); 4 quarters of losses (operating loss in each of the last four quarters); Control change (change of largest shareholder, or a contract that would cause one (90 days)); Private placement (third-party allotment rights offering decided in the past 90 days). 2 more signals are shown on the page. These are factual flags, not investment advice.
Which companies are in the same industry as MOA Life Plus?: Under the Korean Standard Industrial Classification recorded on DART, MOA Life Plus is grouped with 77 other listed companies in research & development. The most covered in Korean news over the past 30 days are Alteogen, SK biopharmaceuticals and Onconic Therapeutics.